Novel biologic mechanisms of levosimendan and its effect on the failing heart

Expert Opinion on Investigational Drugs

Volumn 17, Issue 8, 2008, Pages 1143-1150

  Parissis, John T ^a   Andreadou, Ioanna ^a   Bistola, Vassiliki ^a   Paraskevaidis, Ioannis ^a   Filippatos, Gerasimos ^a   Kremastinos, Dimitrios T ^a  

^a UNIVERSITY OF ATHENS   (Greece)

Author keywords

Endothelial function; Heart failure; Hemodynamics; Inflammation; Levosimendan; Oxidative stress; Preconditioning

Indexed keywords

3 NITROTYROSINE; ADENOSINE TRIPHOSPHATE SENSITIVE POTASSIUM CHANNEL; BRAIN NATRIURETIC PEPTIDE; CALCIUM; CARBONYL DERIVATIVE; CYCLIC GMP; DOBUTAMINE; HYDROGEN PEROXIDE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; LEVOSIMENDAN; MALONALDEHYDE; N [4 (1,4,5,6 TETRAHYDRO 4 METHYL 6 OXO 3 PYRIDAZINYL)PHENYL]ACETAMIDE; NITRIC OXIDE; OXYGEN; PLACEBO; TROPONIN C; TROPONIN I; TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1; CARDIOTONIC AGENT; HYDRAZONE DERIVATIVE; PYRIDAZINE DERIVATIVE; SIMENDAN;

ACUTE HEART FAILURE; ANTIOXIDANT ACTIVITY; APOPTOSIS; CELL DEATH; CHANNEL GATING; CLINICAL TRIAL; DISEASE COURSE; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; EMBASE; HEADACHE; HEART FAILURE; HEART HEMODYNAMICS; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE; HEART MUSCLE CELL; HEART MUSCLE CONTRACTILITY; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HUMAN; HYPOKALEMIA; HYPOTENSION; IMMUNE RESPONSE; IMMUNOMODULATION; INOTROPISM; ISCHEMIC HEART DISEASE; ISCHEMIC PRECONDITIONING; LOADING DRUG DOSE; MEDICAL LITERATURE; MEDLINE; NEUROENDOCRINOLOGY; NITROSATIVE STRESS; OXIDATIVE STRESS; OXYGEN CONSUMPTION; PEER REVIEW; PLEIOTROPY; PROGNOSIS; REVIEW; SURVIVAL RATE; TREATMENT OUTCOME; VASODILATATION; DRUG EFFECT; HEART CONTRACTION; METABOLISM; PATHOLOGY; RANDOMIZED CONTROLLED TRIAL;

CARDIOTONIC AGENTS; HEART FAILURE; HUMANS; HYDRAZONES; MYOCARDIAL CONTRACTION; OXIDATIVE STRESS; PYRIDAZINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 51449089894     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.17.8.1143     Document Type: Review

References (69)

1. Adams KF Jr, Fonarow GC, Emerman CL, et al. Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). Am Heart J 2005; 149:209-16
2. Felker GM, O'Connor CM. Inotropic therapy for heart failure: an evidence-based approach. Am Heart J 2001;142:393-401
3. Nieminen MS, Bohm M, Cowie MR, et al. Executive summary of the guidelines on the diagnosis and treatment of acute heart failure: the Task Force on Acute Heart Failure of the European Society of Cardiology. Eur Heart J 2005;26:384-416
4. Parissis JT, Farmakis D, Nieminen M. Classical inotropes and new cardiac enhancers. Heart Fail Rev 2007;12:149-56
5. Kass DA, Solaro RJ. Mechanisms and use of calcium-sensitizitig agents in the failing heart. Circulation 2006; 113:305-15
6. Parissis JT, Filippatos G, Farmakis D, Adamopoulos S, Paraskevaidis I, Kremastinos D. Levosimendan for the treatment of acute heart failure syndromes. Expert Opin Pharmacother 2005;6:2741-51
7. Haikala H, Kaivola J, Nissinen E, et al. Cardiac troponin C as a target protein for a novel calcium sensitizing drug, levosimendan. J Mol Cell Cardiol 1995;27:1859-66
8. Haikala H, Levijoki J, Linden IB. Troponin C-mediated calcium sensitization by levosimendan accelerates the proportional development of isometric tension. J Mol Cell Cardiol 1995;27:2155-65
9. Sorsa T, Heikkinen S, Abott MB, et al. Binding of levosimendan, a calcium sensitizer, to cardiac troponin C. J Biol Chem 2001;276:9337-43
10. Tachibana H, Cheng HJ, Ukai T, et al. Levosimendan improves LV systolic and diastolic performance at rest and during exercise after heart failure. Am J Physiol Heart Circ Physiol 2005;88.H914-22
11. Slawsky MT, Colucci WS, Gottlieb SS, et al. Acute hemodynamic and clinical effects of levosimendan in patients with severe heart failure. Study Investigators. Circulation 2000;102:2222-7
12. Follath F, Cleland JG, Just H, et al. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. Lancet 2002;360:196-202
13. Takahashi R, Endoh M. Dual regulation of myofilament Ca2+ sensitivity by levosimendan in normal and acidotic conditions in aequorin-loaded canine ventricular myocardium. Br J Pharmacol 2005;145:1143-52
14. Hasenfuss G, Pieske B, Castell M, et al. Influence of the novel inotropic agent levosimendan on isometric tension and calcium cycling in failing human myocardium. Circulation 1998;98:2141-7
15. Yokoshiki H, Katsube Y, Sunagawa M, Sperelakis N. Levosimendan, a novel Ca2+ sensitizer, activates the glibenclamide-sensitive K+ channel in rat arterial myocytes. Eur J Pharmacol 1997;333:249-59
16. Yokoshiki H, Katsube Y, Sunagawa M, Sperelakis N. The novel calcium sensitizer levosimendan activates the ATP-sensitive K+ channel in rat ventricular cells. J Pharmacol Exp Ther 1997;283:375 -83
17. Kopustinskiene DM, Pollesello P, Saris NE. Levosimendan is a mitochondrial K(ATP) channel opener. Eur J Pharmacol 2001;428:311-4
18. Pataricza J, Krassoi I, Hohn J, et al. Functional role of potassium channels in the vasodilating mechanism of levosimendan in porcine isolated coronary artery. Cardiovasc Drugs Ther 2003;17:115-21
19. Pataricza J, Hohn J, Petri A, et al. Comparison of the vasorelaxing effect of cromakalim and the new inodilator, levosimendan, in human isolated portal vein. J Pharm Pharmacol 2000;52:213-7
20. Hohn J, Pataricza J, Petri A, et al. Levosimendan interacts with potassium channel blockers in human saphenous veins. Basic Clin Pharmacol Toxicol 2004;94:271-3
21. Pataricza J, Szolnoky J, Krassoi I, et al. Vasorelaxing effect of levosimendan against 5-hydroxytryptamine-induced contractions in isolated human conduit bypass grafts. J Pharm Pharmacol 2006;58:1107-12
22. De Witt BJ, Ibrahim IN, Bayer E, et al. An analysis of responses to levosimendan in the pulmonary vascular bed of the cat. Anesth Analg 2002;94:1427-33
23. Leather HA, Ver Eycken K, Segers P, et al. Effects of levosimendan on right ventricular function and ventriculovascular coupling in open chest pigs. Crit Care Med 2003;31:2339-43
24. Mebazaa A, Nieminen MS, Packer M, et al. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE Randomized Trial. JAMA 2007;297:1883-91
25. Giannakoulas G, Giannoglou G, Vassilikos V, et al. Clinical significance of acute neurohormonal response after levosimendan treatment. Am J Cardiol 2006;98:1123-4
26. Parissis JT, Panou F, Farmakis D, et al. Effects of levosimendan on markers of left ventricular diastolic function and neurohormonal activation in patients with advanced heart failure. Am J Cardiol 2005;96:423-6
27. Adamopoulos S, Parissis JT, Iliodromitis EK, et al. Effects of levosimendan versus dobutamine on inflammatory and apoptotic pathways in acutely decompensated chronic heart failure. Am J Cardiol 2006;98:102-6
28. Mueller T, Gegenhuber A, Haltmayer M. Levosimendan reduces plasma amino terminal proBNP in patients with decompensated heart failure. Int J Cardiol 2005;104:355-6; author reply 357-8
29. Sundberg S, Lilleberg J, Nieminen MS, Lehtonen L. Hemodynamic and neurohumoral effects of levosimendan, a new calcium sensitizer, at rest and during exercise in healthy men. Am J Cardiol 1995;75:1061-6
30. De Luca L, Colucci WS, Nieminen MS, et al. Evidence-based use of levosimendan in different clinical settings. Eur Heart J 2006;27:1908-20
31. Parissis JT, Adamopoulos S, Antoniades C, et al. Effects of levosimendan on circulating pro-inflammatory cytokines and soluble apoptosis mediators in patients with decompensated advanced heart failure. Am J Cardiol 2004;93:1309-12
32. +- sensitizer levosimendan improves oxidative damage, BNP and pro-inflammatory cytokine levels in patients with advanced decompensated heart failure in comparison to dobutamine. Eur J Heart Fail 2005;7:882-7
33. Trikas A, Antoniades C, Latsios G, et al. Long-term effects of levosimendan infusion on inflammatory processes and sFas in patients with severe heart failure. Eur J Heart Fail 2006;8:804-9
34. Kyrzopoulos S, Adamopoulos S, Parissis JT, et al. Levosimendan reduces plasma B-type natriuretic peptide and interleukin 6, and improves central hemodynamics in severe heart failure patients. Int J Cardiol 2005;99:409-13
35. Lilleberg J, Laine M, Palkama T, et al. Duration of the haemodynamic action of a 24-h infusion of levosimendan in patients with congestive heart failure. Eur J Heart Fail 2007;9:75-82
36. Hasenfuss G, Pieske B, Kretschmann B, et al. Effects of calcium sensitizers on intracellular calcium handling and myocardial energetics. J Cardiovasc Pharmacol 1995;26(Suppl 1):S45-51
37. Adamopoulos S, Parissis JT, Kremastinos DT. A glossary of circulating cytokines in chronic heart failure. Eur J Heart Fail 2001;3:517-26
38. Fischer D, Rossa S, Landmesser U, et al. Endothelial dysfunction in patients with chronic heart failure is independently associated with increased incidence of hospitalization, cardiac transplantation, or death. Eur Heart J 2005;26:65-9
39. Parissis JT, Karavidas A, Bistola V, et al. Effects of levosimendan on flow-mediated vasodilation and soluble adhesion molecules in patients with advanced chronic heart failure. Atherosclerosis 2007;197:278-83
40. Grossini E, Caimmi PP, Molinari C, et al. Hemodynamic effect of intracoronary administration of levosimendan in the anesthetized pig. J Cardiovasc Pharmacol 2005;46:333-42
41. Michaels AD, McKeown B, Kostal M, et al. Effects of intrávenous levosimendan on human coronary vasomotor regulation, left ventricular wall stress, and myocardial oxygen uptake. Circulation 2005;111:1504-9
42. Ikonomidis I, Parissis JT, Paraskevaidis I, et al. Effects of levosimendan on coronary artery fl ow and cardiac performance in patients with advanced heart failure. Eur J Heart Fail 2007;9:1172-7
43. De Luca L, Proietti P, Celotto A, et al. Levosimendan improves hemodynamics and coronary flow reserve after percutaneous coronary intervention in patients with acute myocardial infarction and left ventricular dysfunction. Am Heart J 2005;150:563-8
44. Uchiyama Y, Otani H, Okada T, et al. Integrated pharmacological preconditioning in combination with adenosine, a mitochondrial KATP channel opener and a nitric oxide donor. J Thorac Cardiovasc Surg 2003;126:148-59
45. Eisen A, Fisman EZ, Rubenfire M, et al. Ischemic preconditioning: nearly two decades of research. A comprehensive review. Atherosclerosis 2004;172:201-10
46. Kersten JR, Montgomery MW, Pagel PS, Warltier DC. Levosimendan, a new positive inotropic drug, decreases myocardial infarct size via activation of K(ATP) channels. Anesth Analg 2000;90:5-11
47. Kopustinskiene DM, Pollesello P, Saris NE. Potassium-specific effects of levosimendan on heart mitochondria. Biochem Pharmacol 2004;68:807-12
48. Vegh A, Szekeres L, Parratt J. Preconditioning of the ischaemic myocardium; involvement of the L-arginine nitric oxide pathway. Br J Pharmacol 1992;107:648-52
49. Horimoto H, Gaudette GR, Saltman AE, Krukenkamp IB. The role of nitric oxide, K(+)(ATP) channels, and cGMP in the preconditioning response of the rabbit. J Surg Res 2000;92:56-63
50. Ignarro LJ, Cirino G, Casini A, Napoli C. Nitric oxide as a signaling molecule in the vascular system: an overview. J Cardiovasc Pharmacol 1999;34:879-86
51. Du Toit EF, Muller CA, McCarthy J, Opie LH. Levosimendan: effects of a calcium sensitizer on function and arrhythmias and cyclic nucleotide levels during ischemia/reperfusion in the Langendorff-perfused guinea pig heart. J Pharmacol Exp Ther 1999;290:505-14
52. Parissis JT, Andreadou I, Markantonis SL, et al. Effects of levosimendan on circulating markers of oxidative and nitrosative stress in patients with advanced heart failure. Atherosclerosis 2007;195:e210-5
53. Toller WG, Stranz C. Levosimendan, a new inotropic and vasodilator agent. Anesthesiology 2006;104:556-69
54. Szilagyi S, Pollesello P, Levijoki J, et al. The effects of levosimendan and OR-1896 on isolated hearts, myocyte-sized preparations and phosphodiesterase enzymes of the guinea pig. Eur J Pharmacol 2004;486:67-74
55. Kudej RK, Zhang XP, Ghaleh B, et al. Enhanced cAMP-induced nitric oxide-dependent coronary dilation during myocardial stunning in conscious pigs. Am J Physiol Heart Circ Physiol 2000;279:H2967-74
56. Ferrari R, Guardigli G, Mele D, et al. Oxidative stress during myocardial ischaemia and heart failure. Curr Pharm Des 2004;10:1699-711
57. Sorescu D, Griendling KK. Reactive oxygen species, mitochondria, and NAD(P)H oxidases in the development and progression of heart failure. Congest Heart Fail 2002;8:132-40
58. Castro PF, Greig D, Perez O, et al. Relation between oxidative stress, catecholamines, and impaired chronotropic response to exercise in patients with chronic heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol 2003;92:215-8
59. Pimentel DR, Amin JK, Xiao L, et al. Reactive oxygen species mediate amplitude-dependent hypertrophic and apoptotic responses to mechanical stretch in cardiac myocytes. Circ Res 2001;89:453-60
60. Communal C, Singh K, Pimentel DR, Colucci WS. Norepinephrine stimulates apoptosis in adult rat ventricular myocytes by activation of the beta-adrenergic pathway. Circulation 1998;98:1329-34
61. +/calmodulin kinase II. J Clin Invest 2003;111:617-25
62. Maytin M, Colucci WS. Cardioprotection: a new paradigm in the management of acute heart failure syndromes. Am J Cardiol 2005;96:G26-31
63. Sahin AS, Gormus N, Duman A. Preconditioning with levosimendan prevents contractile dysfunction due to H2O2-induced oxidative stress in human myocardium. J Cardiovasc Pharmacol 2007;50:419-23
64. Yakut N, Yasa H, Bahriye Lafci B, et al. The influence of levosimendan and iloprost on renal ischemia-reperfusion: an experimental study. Interact Cardiovasc Thorac Surg 2008;7:235-9
65. Turko IV, Murad F. Protein nitration in cardiovascular diseases. Pharmacol Rev 2002;54:619-34
66. Mihm MJ, Coyle CM, Schanbacher BL, et al. Peroxynitrite-induced nitration and inactivation of myofibrillar creatine kinase in experimental heart failure. Cardiovasc Res 2001;49:798-807
67. Mungrue IN, Gros R, You X, et al. Cardiomyocyte overexpression of iNOS in mice results in peroxynitrite generation, heart block, and sudden death. J Clin Invest 2002;109:735-43
68. Arstall MA, Sawyer DB, Fukazawa R, Kelly RA. Cytokine-mediated apoptosis in cardiac myocytes: the role of inducible nitric oxide synthase induction and peroxynitrite generation. Circ Res 1999;85:829-40
69. Ischiropoulos H. Biological tyrosine nitration: a pathophysiological function of nitric oxide and reactive oxygen species. Arch Biochem Biophys 1998;356:1-11